
Biomarkers (BMKs) have become fundamental tools in drug development, accelerating and optimizing targeted therapeutic innovation. As a bioanalytical CRO with over 15 years of experience in biomarker analysis, we’ve seen firsthand how the strategic integration of biomarkers can accelerate drug programs, help meet evolving regulatory standards,…

In Episode 89 of The Weekly Bioanalysis, hosts Dominic Warrino and John Perkins engage in a compelling conversation with special guest, Jeff Goddard, Senior Vice President of Corporate Development at KCAS Bio. The three delve into KCAS Bio’s strategic growth, including the acquisition of France-based Active Biomarkers, which expanded the company’s transatlantic…

In Episode 88 of The Weekly Bioanalysis, hosts Dominic Warrino, Ph.D. and John Perkins, Ph.D present a special WRIB 2025 recap featuring several KCAS Bio scientists who share firsthand insights from their presentations at the major bioanalytical conference. David Ambrose highlights KCAS Bio’s global harmonization of spectral flow cytometry instruments across…

KCAS Bio offers a wide range of biomarker services, from cell-based to soluble biomarker analysis, including ligand binding assays (LBA), across a variety of matrix types. Soluble biomarker analysis can be achieved on multiple platforms depending on factors such as sample type, required sensitivity, and whether multiplexing is…

We were happy to participate in the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, held from April 1 to 5, 2025, in Vienna, Austria. The conference was a valuable opportunity to connect with experts, share our experience, and gain insights…

Discover innovative insights into bioanalytical method development with our poster, presented by Christine Bain, Ph.D., at ECCO 2025. This work explores the creation and application of reference samples containing endogenous immune mediators—such as cytokines and chemokines—to effectively evaluate the performance of bioanalytical methods. Download the poster now to learn more…

In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company’s collaboration with KCAS Bio and introduces their…

When it comes to developing new therapies for inflammatory bowel diseases (IBD), having robust and reliable bioanalytical support is crucial. From the early stages of drug discovery to Phase III clinical trials, our comprehensive bioanalytical solutions are designed to enhance and accelerate your drug development journey in a GCP…

During episode 86 of KCAS Bio’s “The Weekly Bioanalysis” podcast, our hosts Dom and John are joined by Dr Cheikh Kane, the Vice President of Biopharma Services at KCAS Bio, to discuss immunogenicity. They first define Immunogenicity; what it is and why it is tested, as well as the standard…

Dom and John, the hosts of “The Weekly Bioanalysis”, recently returned from EBF in Barcelona where there was a session on Patient-centric Microsampling, which both of them found fascinating. This inspired both of them to decide it was high time to revisit this part of our industry. In spite of…

Biomarker assay development is pivotal to clinical research and the success of a study, yet the journey from qualification to validation is often complex. In this blog, we discuss four must-know essentials to optimize your assay development process. 1. Understand the Context of Use: Qualification vs. Validation The FDA emphasizes…

In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how…